Kartläggning av användningsmönstret av Menopausal Hormone Therapy (MHT)

Background Menopausal hormone therapy (MHT) is used to treat menopausal symptoms. The use of MHT decreased after the Women's Health Initiative (WHI) study which proved an increased risk of stroke and breast cancer. In 2019 the Swedish Medical Products Agency was commissioned to update the treatment recommendations of MHT. Aim To conduct a review of studies analyzing the use of MHT through the literature, and to describe the use of MHT in Sweden. Methods A literature study assessing published studies on MHT use from different countries, by using PubMed database and publications found at various Swedish authorities’ websites such as the Swedish Medical Products Agency and the National Board of Health and Welfare between 2003 and 2020 that fulfilled the purpose.A register study to analyze MHT use in the Swedish female population between 2008 – 2019 for women between 40 – 59 years. The databases used was the National Board of Health and Welfare's patient register and the Swedish Prescribed Drug Register Results There is a large variation in MHT utilization between countries due to differences in guidelines and other factors.In Sweden, the use of MHT was low in comparison with other countries, women had more knowledge about the treatment and prescribers followed the Swedish Medical Products Agency's recommendations.In 2019, the increase in patients diagnosed with menopause was twice as high as it was in 2008. in addition, the use of (MHT) in Sweden increased in the period 2017 - 2020. The most widely used MHT group was estrogen. Conclusions MHT use has increased in the Swedish population between 2017 and 2020, further knowledge of the benefit- risk profile is neede